BDRX Stock Overview A clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Biodexa Pharmaceuticals Plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Biodexa Pharmaceuticals Historical stock prices Current Share Price US$4.52 52 Week High US$74.00 52 Week Low US$3.50 Beta 1.47 1 Month Change 1.57% 3 Month Change -13.90% 1 Year Change -91.01% 3 Year Change -99.99% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer Oct 17
Biodexa Announces Successful Appeal of Nasdaq Delisting Oct 16
Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Oct 04
First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023) Sep 29 Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas Sep 16
Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal Aug 31 See more updates
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer Oct 17
Biodexa Announces Successful Appeal of Nasdaq Delisting Oct 16
Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Oct 04
First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023) Sep 29 Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas Sep 16
Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal Aug 31 Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009969 million. Jul 25
Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009968 million. Jul 24
Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data Jul 12
Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 Jul 02
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ At 12 Months in Familial Adenomatous Polyposis (Fap) Jun 24
Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis Jun 05
Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting May 23
Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024 May 18
Full year 2023 earnings released: UK£8.00 loss per share (vs UK£620 loss in FY 2022) Apr 19
New minor risk - Financial data availability Apr 16
Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers Mar 29
New major risk - Share price stability Mar 29
Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Feb 24
New major risk - Financial position Feb 10
Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients Feb 09
Biodexa Appoints Ann Merchant to the Board of Directors Dec 29 Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million. Dec 21
First half 2023 earnings released: UK£14.39 loss per share (vs UK£249 loss in 1H 2022) Oct 05
Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma Oct 05
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano) Sep 22
Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement Jul 25
Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs) Jul 11
Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination Jul 08
Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015 Jul 07
Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule Jun 21
Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements Jun 16
Biodexa Pharmaceuticals Plc announced that it has received $3.320388 million in funding Jun 08
Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023 May 23 Biodexa Pharmaceuticals Plc (NasdaqCM:BDRX) entered into non-binding letter of intent to acquire Varian Biopharmaceuticals Inc. for $3.7 million. May 19
Full year 2022 earnings released: UK£0.077 loss per share (vs UK£1.36 loss in FY 2021) May 01 Midatech Pharma plc announced that it has received $5.999223 million in funding Feb 19
Midatech Pharma Announces Receipt of NASDAQ Notice Feb 04
Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study Jan 12 Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million. Midatech Pharma plc announced that it expects to receive $10 million in funding Dec 14
Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110 Nov 14
Midatech Pharma plc Announces Receipt of Nasdaq Notification Oct 19
Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement Oct 18
Midatech Pharma reports 1H results Sep 14 Midatech Pharma PLC Announces Directorate Change Jun 21
Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022 Jun 11 Midatech Pharma plc Announces Retirement of Rolf Stahel
Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma Jun 02
Midatech Pharma plc, Annual General Meeting, Jun 20, 2022 May 25
Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement Apr 15
Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective Dec 14
Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million. Jun 30 Midatech Pharma plc Announces Shut Down of its Bilbao Operations
Midatech surges on the promise of drug delivery system Jun 17
Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan Dec 13
Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study Oct 20
Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020 Aug 28
Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million. Jul 31 Shareholder Returns BDRX US Biotechs US Market 7D 0.4% -2.4% -2.1% 1Y -91.0% -8.7% 21.3%
See full shareholder returns
Return vs Industry: BDRX underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: BDRX underperformed the US Market which returned 23.2% over the past year.
Price Volatility Is BDRX's price volatile compared to industry and market? BDRX volatility BDRX Average Weekly Movement 26.1% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: BDRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BDRX's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.
Show more Biodexa Pharmaceuticals Plc Fundamentals Summary How do Biodexa Pharmaceuticals's earnings and revenue compare to its market cap? BDRX fundamental statistics Market cap US$2.48m Earnings (TTM ) -US$8.32m Revenue (TTM ) US$101.33k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BDRX income statement (TTM ) Revenue UK£83.00k Cost of Revenue -UK£62.00k Gross Profit UK£145.00k Other Expenses UK£6.96m Earnings -UK£6.82m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -11.74 Gross Margin 174.70% Net Profit Margin -8,215.66% Debt/Equity Ratio 0%
How did BDRX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 00:04 End of Day Share Price 2025/01/10 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Biodexa Pharmaceuticals Plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aydin Huseynov Ladenburg Thalmann & Company Savvas Neophitou Panmure Liberum Historic (Panmure Gordon) Jens Lindqvist Singer Capital Markets
Show 0 more analysts 
